CANCER

Imugene's promising trial results: five patients with >30% decrease in tumour size

Finfeed Archived Dec 17, 2018

Imugene (ASX:IMU) has met all study endpoints and produced positive top-line results from its Phase 1b study of its HER-Vaxx gastric cancer vaccine.

Can a tortoise cure cancer?

Finfeed Archived Dec 05, 2018

Long living tortoises may be the key to curing cancer and living longer.

Immuron appoints a new CEO to lead it into the future

Finfeed Archived Nov 19, 2018

Immuron (ASX:IMC) has just appointed a well-credentialled CEO to help it develop and commercialise its many treatments of many gut mediated diseases.

Imugene's gastric cancer immuno-oncology trial advances to Phase 2

Finfeed Archived Nov 13, 2018

Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), today announced preparations are underway to begin the Phase 2 study of its HER-Vaxx cancer vaccine in gastric cancer patients in early 2019.

Good run continues for Imugene with $1.85M R&D tax incentive

Finfeed Archived Nov 09, 2018

Imugene Limited (ASX:IMU) has today announced that it has received a research and development (R&D) tax refund of $1.85 million as part of the Australian government’s R&D tax incentive scheme. The incentive recognises the important immuno-oncology research activities undertaken by the ASX small cap during the financial year ended 30 June 2018.

Race Oncology pens key deal to seek chemo drug Bisantrene licensing

Finfeed Archived Nov 01, 2018

Race Oncology (ASX:RAC) has come to agreement with Biosynergy to pursue licensing deals for chemotherapy drug, Bisantrene.

ASX Biotech Eyes International Distribution of Overlooked Cancer Drug

Next Investors Archived Oct 30, 2018

Today’s biotech junior is in the business of repurposing late-stage drug assets that have been overlooked by big pharma.

Prescient onboards former Array Biopharma executive

Finfeed Archived Oct 29, 2018

Clinical-stage oncology company, Prescient Therapeutics Ltd (ASX:PTX), has appointed leading drug discovery and development executive, Dr James Winkler, as Vice President for business development based in the US.

Rhythm Biosciences surges 80% as catalysts emerge

Finfeed Archived Oct 24, 2018

Rhythm Bioscences (ASX:RHY) surged in share price under expectation that it will successfully complete the next phase of its key reagent development program by the end of 2018.